Article
Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial
Registro en:
SANTOS, Daiane Santos dos; et al. Chemoprophylaxis of leprosy with rifampicin in contacts of multibacillary patients: study protocol for a randomized controlled trial. Trials, v.19, n.244, 10p, 2018.
1745-6215
10.1186/s13063-018-2623-6
Autor
Santos, Daiane Santos dos
Duppre, Nádia Cristina
Sarno, Euzenir Nunes
Pinheiro, Roberta Olmo
Sales, Anna Maria
Nery, José Augusto da Costa
Moraes, Milton Ozório
Camacho, Luiz Antônio Bastos
Resumen
The annual new-case detection rate for leprosy, while generally stable over the last decade, shows that transmission rates have remained stagnant despite the successful worldwide administration of multidrug therapy since the 1980s. As such, novel control strategies are urgently needed. Focusing on managing leprosy patient contacts, the most susceptible to contracting the disease, has been seen as a potential strategy in limiting the spread of leprosy as shown by a number of recent epidemiological studies. Immunoprophylaxis with Bacillus Calmette-Guérin (BCG) has been seen as an effective preventive measure due to its ability to stimulate the development of cellular immunity which is essential in controlling the disease, especially in its multibacillary (MB) forms. The association of immunoprophylaxis with chemoprophylaxis in a single dose of rifampicin has been shown to be a promising preventive strategy, although a variety of studies have found instances of early case detection just a few months after BCG vaccination.